losartan has been researched along with Cicatrix in 15 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Cicatrix: The fibrous tissue that replaces normal tissue during the process of WOUND HEALING.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to examine the effect of topical and/or oral angiotensin converting enzyme II inhibitor and TGF-beta signaling blocker losartan on corneal stromal fibrosis that developed in rabbit corneas after Descemetorhexis removal of central Descemet's membrane and corneal endothelium." | 8.12 | Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet's membrane-endothelial excision in rabbits. ( Hilgert, GSL; Murillo, SE; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022) |
| "To evaluate the efficacy of losartan and prednisolone acetate in inhibiting corneal scarring fibrosis after alkali burn injury in rabbits." | 8.12 | Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury. ( Hilgert, GSL; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022) |
| " Because aldosterone production in the heart increases after myocardial infarction (MI), we investigated the effect of chronic administration of spironolactone, an aldosterone receptor antagonist, in rats after MI compared with the effects produced by losartan and hydralazine." | 7.72 | Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. ( de Resende, MM; Gomes, Mda G; Leite, CM; Milanez, Mda C; Mill, JG, 2003) |
| "Losartan is an angiotensin II receptor blocker (ARB) that impedes transforming growth factor (TGF) beta signaling by inhibiting activation of signal transduction molecule extracellular signal-regulated kinase (ERK)." | 7.01 | Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders. ( Wilson, SE, 2023) |
| "The purpose of this study was to examine the effect of topical and/or oral angiotensin converting enzyme II inhibitor and TGF-beta signaling blocker losartan on corneal stromal fibrosis that developed in rabbit corneas after Descemetorhexis removal of central Descemet's membrane and corneal endothelium." | 4.12 | Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet's membrane-endothelial excision in rabbits. ( Hilgert, GSL; Murillo, SE; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022) |
| "To evaluate the efficacy of losartan and prednisolone acetate in inhibiting corneal scarring fibrosis after alkali burn injury in rabbits." | 4.12 | Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury. ( Hilgert, GSL; Sampaio, LP; Santhiago, MR; Shiju, TM; Wilson, SE, 2022) |
| "When compared with MDSC transplantation alone, MDSC/losartan treatment resulted in significantly decreased scar formation, an increase in the number of regenerating myofibers, and improved functional recovery after muscle contusions." | 3.83 | The Combined Use of Losartan and Muscle-Derived Stem Cells Significantly Improves the Functional Recovery of Muscle in a Young Mouse Model of Contusion Injuries. ( Fu, FH; Huard, J; Kawakami, Y; Kobayashi, M; Ota, S; Otsuka, T; Terada, S, 2016) |
| " Because aldosterone production in the heart increases after myocardial infarction (MI), we investigated the effect of chronic administration of spironolactone, an aldosterone receptor antagonist, in rats after MI compared with the effects produced by losartan and hydralazine." | 3.72 | Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. ( de Resende, MM; Gomes, Mda G; Leite, CM; Milanez, Mda C; Mill, JG, 2003) |
| "Losartan ointment was well tolerated with no complication." | 3.11 | Efficacy of Topical Losartan in Management of Mammoplasty and Abdominoplasty Scars: A Randomized, Double-Blind Clinical Trial. ( Haddady Abianeh, S; Khodaei, B; Motavalli Khiavi, F; Nasimi, M; Nassireslami, E; Rahmati, J; Seyedpour, S, 2022) |
| "Losartan is an angiotensin II receptor blocker (ARB) that impedes transforming growth factor (TGF) beta signaling by inhibiting activation of signal transduction molecule extracellular signal-regulated kinase (ERK)." | 3.01 | Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders. ( Wilson, SE, 2023) |
| "The scarring is driven by inflammatory processes, particularly the TGF-β signaling pathways, resulting in excess synthesis and deposition of the extracellular matrix, especially collagen." | 1.72 | Losartan treatment improves recessive dystrophic epidermolysis bullosa: A case series. ( Abdollahimajd, F; Hajimoradi, B; Mansouri, P; Pourani, MR; Rakhshan, A; Uitto, J; Vahidnezhad, H; Youssefian, L, 2022) |
| "With all results of anti-scarring, the compound losartan cream (containing chitosan, asiaticoside, and losartan) shows the best effect, followed by the chitosan asiaticoside cream." | 1.72 | The compound losartan cream inhibits scar formation via TGF-β/Smad pathway. ( Du, YZ; Fang, QQ; Lou, D; Shi, BH; Tan, WQ; Wang, XF; Wang, ZC; Xuan, GD; Zhang, LY; Zhao, WY, 2022) |
| "The harvested scar tissues were analyzed with H&E staining, Masson staining and immunohistochemical staining." | 1.51 | The effect of topical ramipril and losartan cream in inhibiting scar formation. ( Chen, CY; Fang, QQ; Hu, YY; Ma, L; Shi, BH; Shi, P; Tan, WQ; Wang, XF; Zhang, LY; Zhang, MX; Zhao, WY; Zheng, B, 2019) |
| "Treatment with Losartan and to a lesser extent the combination therapy resulted in diminished graft take, increased wound contraction and poorer scar outcome." | 1.46 | Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds. ( Akershoek, JJ; Beelen, RHJ; Boekema, BKHL; Brouwer, KM; Middelkoop, E; Ulrich, MMW; Vlig, M, 2017) |
| "To examine the effects of losartan on scar formation after trabeculectomy and on fibrotic changes of human Tenon's fibroblasts (HTFs)." | 1.46 | Losartan Attenuates Scar Formation in Filtering Bleb After Trabeculectomy. ( Fu, S; Shi, H; Wang, H; Xiao, Y; Xu, K; Ye, W; Zhang, X, 2017) |
| "Losartan-treated rats exhibited a significantly less marked reduction in vascular perfusion and a significantly lesser extent of tissue hypoxia." | 1.33 | The scar neovasculature after myocardial infarction in rats. ( Ansari, R; Kiani, MF; Postlethwaite, AE; Sun, Y; Wang, B; Weber, KT, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 8 (53.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sampaio, LP | 2 |
| Hilgert, GSL | 2 |
| Shiju, TM | 2 |
| Murillo, SE | 1 |
| Santhiago, MR | 2 |
| Wilson, SE | 3 |
| Pourani, MR | 1 |
| Vahidnezhad, H | 1 |
| Mansouri, P | 1 |
| Youssefian, L | 1 |
| Rakhshan, A | 1 |
| Hajimoradi, B | 1 |
| Abdollahimajd, F | 1 |
| Uitto, J | 1 |
| Khodaei, B | 2 |
| Nasimi, M | 2 |
| Nassireslami, E | 1 |
| Seyedpour, S | 2 |
| Rahmati, J | 1 |
| Haddady Abianeh, S | 1 |
| Motavalli Khiavi, F | 2 |
| Tian, F | 1 |
| Jia, Y | 1 |
| Yuan, FL | 1 |
| Yuan, ZD | 1 |
| Wu, JJ | 1 |
| Li, YY | 1 |
| Zhang, KW | 1 |
| Guo, DY | 1 |
| Chen, WW | 1 |
| Chen, MN | 1 |
| Chen, ZH | 1 |
| Li, X | 1 |
| Zhao, WY | 2 |
| Zhang, LY | 2 |
| Wang, ZC | 1 |
| Fang, QQ | 2 |
| Wang, XF | 2 |
| Du, YZ | 1 |
| Shi, BH | 2 |
| Lou, D | 1 |
| Xuan, GD | 1 |
| Tan, WQ | 2 |
| Zheng, B | 1 |
| Chen, CY | 1 |
| Zhang, MX | 1 |
| Hu, YY | 1 |
| Shi, P | 1 |
| Ma, L | 1 |
| Akershoek, JJ | 1 |
| Brouwer, KM | 1 |
| Vlig, M | 1 |
| Boekema, BKHL | 1 |
| Beelen, RHJ | 1 |
| Middelkoop, E | 1 |
| Ulrich, MMW | 1 |
| Kobayashi, M | 1 |
| Ota, S | 1 |
| Terada, S | 1 |
| Kawakami, Y | 1 |
| Otsuka, T | 1 |
| Fu, FH | 1 |
| Huard, J | 1 |
| Shi, H | 1 |
| Wang, H | 1 |
| Fu, S | 1 |
| Xu, K | 1 |
| Zhang, X | 1 |
| Xiao, Y | 1 |
| Ye, W | 1 |
| Mill, JG | 1 |
| Milanez, Mda C | 1 |
| de Resende, MM | 1 |
| Gomes, Mda G | 1 |
| Leite, CM | 1 |
| Guo, X | 1 |
| Chapman, D | 1 |
| Dhalla, NS | 1 |
| Wang, B | 1 |
| Ansari, R | 1 |
| Sun, Y | 1 |
| Postlethwaite, AE | 1 |
| Weber, KT | 1 |
| Kiani, MF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Ethosomal Gel Bearing Losartan 5% on The Patient and Observer Scar Assessment Scale Score, Degree of Erythema and Pigmentation, Surface Area, Thickness and Pliability of Human Keloids[NCT05893108] | Phase 1/Phase 2 | 46 participants (Anticipated) | Interventional | 2024-03-30 | Not yet recruiting | ||
| A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for losartan and Cicatrix
| Article | Year |
|---|---|
Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cicatrix; Corne | 2023 |
3 trials available for losartan and Cicatrix
| Article | Year |
|---|---|
Efficacy of Topical Losartan in Management of Mammoplasty and Abdominoplasty Scars: A Randomized, Double-Blind Clinical Trial.
Topics: Abdominoplasty; Angiotensins; Cicatrix; Female; Humans; Losartan; Mammaplasty; Ointments; Treatment | 2022 |
Comments on ''Efficacy of Topical Losartan in Management of Mammoplasty and Abdominoplasty Scars: A Randomized, Double-Blind Clinical Trial''.
Topics: Abdominoplasty; Cicatrix; Double-Blind Method; Humans; Hypertension; Losartan; Mammaplasty; Treatmen | 2023 |
Invited Response on: Comment: "Efficacy of Topical Losartan in Management of Mammoplasty and Abdominoplasty Scars: A Randomized, Double-Blind Clinical Trial".
Topics: Abdominoplasty; Cicatrix; Double-Blind Method; Humans; Hypertension; Losartan; Mammaplasty; Treatmen | 2023 |
11 other studies available for losartan and Cicatrix
| Article | Year |
|---|---|
Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet's membrane-endothelial excision in rabbits.
Topics: Actins; Administration, Ophthalmic; Angiotensin II Type 1 Receptor Blockers; Animals; Cicatrix; Coll | 2022 |
Losartan treatment improves recessive dystrophic epidermolysis bullosa: A case series.
Topics: Animals; Cicatrix; Collagen; Collagen Type VII; Epidermolysis Bullosa Dystrophica; Female; Losartan; | 2022 |
Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury.
Topics: Adrenal Cortex Hormones; Alkalies; Animals; Burns, Chemical; Cicatrix; Collagen Type IV; Corneal Dis | 2022 |
The compound losartan cream inhibits scar formation via TGF-β/Smad pathway.
Topics: Animals; Chitosan; Cicatrix; Losartan; Mice; Ointments; Signal Transduction; Smad Proteins; Transfor | 2022 |
The effect of topical ramipril and losartan cream in inhibiting scar formation.
Topics: Administration, Topical; Animals; Cicatrix; Fibroblasts; Losartan; Male; Mice, Inbred C57BL; Ramipri | 2019 |
Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds.
Topics: Actins; Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Burns; | 2017 |
The Combined Use of Losartan and Muscle-Derived Stem Cells Significantly Improves the Functional Recovery of Muscle in a Young Mouse Model of Contusion Injuries.
Topics: Animals; Cicatrix; Contusions; Disease Models, Animal; Losartan; Mice; Muscle, Skeletal; Myogenic Re | 2016 |
Losartan Attenuates Scar Formation in Filtering Bleb After Trabeculectomy.
Topics: Actins; Aged; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Cell Movement; Ce | 2017 |
Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats.
Topics: Animals; Cicatrix; Collagen; Hydralazine; Losartan; Male; Myocardial Infarction; Myocardium; Organ S | 2003 |
Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blotting, Northern; Blotting, Western; Calci | 2003 |
The scar neovasculature after myocardial infarction in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cicatrix; Losartan; Male; Myocardial Infarction; N | 2005 |